This clinical trial compared intranasal naloxone taken as needed and placebo for the treatment of gambling disorder. The researchers randomly assigned participants to the two groups. The treatment period lasted 12 weeks, with a 2-week follow-up. All participants received psychosocial support. Gambling urge decreased in both groups over the 12-week treatment period. In addition, participants in both groups improved on gambling severity, quality of life, alcohol use, depressive symptoms, and internet use. No differences were observed between the groups for these treatment effects. Intranasal naloxone was safe and well-tolerated. No serious side effects were reported.
